- Acquired by Mitsubishi Tanabe Pharma Corporation, Jul 2017
- Raised $16M funding round, Aug 2014
- Raised $2.5M funding round, Jul 2007
About
NeuroDerm specializes in integrating proprietary pharmaceutical formulations, state-of-the-art delivery system, and digital health solutions with the aim of reducing disease burden and improving the quality of life of patients and their families.
NeuroDerm’s flagship product ND0612 is currently in late stage development for Parkinson’s disease patients experiencing motor fluctuations. Its system for self-administered continuous subcutaneous infusion of the gold standard levodopa/carbidopa, was designed specifically to be a user-friendly system for people with Parkinson's disease, to maintain steady therapeutic levodopa plasma concentrations for the purpose of improving fluctuations, that is, reducing patients’ "OFF" time without increasing troublesome dyskinesia.
Its tailored solution potentially offers sustained relief (compared to oral immediate-release levodopa/carbidopa treatments) and empowers patients and their families to regain control of their lives with greater daily-life predictability and independence.
Funding history · 2 rounds · $63.5M total
Q&A
- What is NeuroDerm's primary focus?
- NeuroDerm specializes in drug-device combination solutions for Central Nervous System Disorders, integrating pharmaceutical formulations, delivery systems, and digital health solutions.
- What is NeuroDerm's flagship product?
- NeuroDerm's flagship product is ND0612, which is in late-stage development for Parkinson's disease patients experiencing motor fluctuations. It is a system for self-administered continuous subcutaneous infusion of levodopa/carbidopa.
- When was NeuroDerm founded?
- NeuroDerm was founded in March 2003.
- What is NeuroDerm's current status?
- NeuroDerm was acquired by Mitsubishi Tanabe Pharma Corporation in July 2017.
- How much funding has NeuroDerm raised in total?
- NeuroDerm has raised a total of $63,500,000 USD.
- Who were the investors in NeuroDerm's August 2014 funding round?
- In August 2014, NeuroDerm raised $16,000,000 USD from The Elias Group.
- How many employees does NeuroDerm have?
- NeuroDerm has 51-200 employees.
- Where is NeuroDerm's headquarters located?
- NeuroDerm's headquarters is located in Rehovot, Center District, Israel.
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | neuroderm.com |
|---|---|
| linkedin.com/company/9873432 | |
| YouTube | youtube.com/@neuroderm8966 |
| Wikidata | wikidata.org/wiki/Q30269158 |
Identifiers & details
| Founded | 2003-3 |
|---|---|
| Employees (exact) | 171 |
| Status reason | Acquired by Mitsubishi Tanabe Pharma Corporation on Jul, 2017 |
| Wikidata QID | Q30269158 |
Acquisitions & public offerings
Acquired by Mitsubishi Tanabe Pharma Corporation 2017-07
Radar intelligence
Patents
| EPO | 67 |
|---|
Publications (Crossref)
| Works | 10 |
|---|
Web history (Wayback)
| Domain | neuroderm.com |
|---|
Wikidata
| QID | Q30269158 |
|---|